Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

When comparing its value to competitor Moderna, NVAX stock can reach $164 by 2024 using probability assessments to adjust for risk. The post Novavax Is Worth 77% More Over the Next 2 Years appeared first on InvestorPlace.

Novavax Is Worth 77% More Over the Next 2 Years

Covid-19 vaccine developer Novavax's stock has declined by almost 31% thus far in 2022, considerably underperforming the S&P 500, which is down by about -4.5% over the same period. Although U.S. Covid-19 daily cases have been surging (over 800,000 over the last week), investors have generally.

Why Novavax Stock Is Already Down 30% This Year

Novavax is expecting approvals from several countries in the coming months and this will take the revenue higher. Buy NVAX stock in the dip.

Novavax Stock May Not Be This Cheap For Long

Novavax Inc (NASDAQ: NVAX) said Wednesday that Australia's national drugs regulator has granted approval for its COVID-19 vaccine. What Happened: The Maryland-based biotechnology company said that Australia's Therapeutic Goods Administration or TGA granted approval for provisional registration of its NVX-CoV2373 vaccine for prevention of COVID-19 in individuals 18 years of age and older.

Novavax Scores Approval From Australian Regulator For COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for provisional  registration of NVX-CoV2373, Novavax' COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

The stock lost its luster last year -- but catalysts are ahead.

Could Novavax Go Parabolic?

It could be on the path to success in Europe.

Here's Some Good News for Novavax That Investors Are Overlooking

Amazon

NextEra Energy

Annaly Capital

Ping Identity Holding Corp

Pubmatic

Trulieve Cannabis Corp.

UnitedHealth Group

Walgreens

Building wealth is easy when you owns stakes in high-quality businesses.

10 Top Stocks That Can Make You Richer in 2022

Vir Biotechnology

The endemic phase of the outbreak should be a boon for these two biotech stocks.

2 Best COVID-19 Growth Stocks to Own in 2022

Adagio Therapeutics

BioNTech SE

Pacific Biosciences of California

Vertex Pharmaceuticals

Could these biotech stocks be poised for gains in 2022?

5 Top Biotech Stocks To Watch In January 2022

The vaccine maker's positive news in recent weeks hasn't been enough to satisfy investors.

What Will It Take for Novavax Stock to Rebound?

Novavax still has not received EUA from the FDA as the market waits for approval. NVAX stock looks like a good buy here, especially if analysts' revenue forecasts for 2022 come to pass as forecast.

Novavax Still Has Not Received an FDA EUA as the Market Waits

Moderna

COVID-19 vaccine stocks are all retreating sharply for a second day running on Friday. The U.S. Supreme Court on Thursday ruled against President Joe Biden's quest to make it mandatory for large businesses employing over 100 people to have their staff vaccinated and undergo weekly testing.

Why Moderna, Novavax And Other Vaccine Stocks Are Extending Losses Today

The vaccine mandate was aimed at private companies with more than 100 employees. The ruling upheld a mandate for healthcare workers.

Moderna and Novavax extend losses after Supreme Court strikes down Biden's vaccine mandate for private employers

Shares of the biotech stocks are getting hit hard after the ruling blocked President Biden's mandate.

Moderna, Novavax, and Other Vaccine Stocks Get Whacked by Supreme Court's Vaccine Decision

NVAX stock just came down to an attractive price, and the future looks bright as Novavax continues its expansion into international markets. The post Here Are a Couple Billion Reasons to Hold Novavax Stock appeared first on InvestorPlace.

Here Are a Couple Billion Reasons to Hold Novavax Stock

Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back following 2021 strength, with investors continuing to weigh sector outlook going into 2022. The US Supreme Court today blocked President Biden's workplace vaccine-or-test mandate for larger employers.

What's Going On With Moderna, BioNTech And Novavax Stock Today

Today, some commentary from Novavax's CEO has investors in NVAX stock re-thinking the bull thesis behind this Covid-19 vaccine play. The post NVAX Stock: One Big Reason Novavax Is Stumbling Today appeared first on InvestorPlace.

NVAX Stock: One Big Reason Novavax Is Stumbling Today

Off and on the price chart, Novavax investors need to be concerned with a mischievous Wall Street bearishly pricing in the news in NVAX stock. The post Novavax Stock Bulls Face an Uphill Challenge appeared first on InvestorPlace.

Novavax Stock Bulls Face an Uphill Challenge

Novavax Stock: Buy, Sell, or Hold in 2022?

Novavax has a lot to look forward to with a surge in Covid-19 cases and a consistent rise in the demand for boosters. Buy NVAX stock.

Novavax Stock Still Has A Solid Chance

It's not too late to invest in this dynamic area.

Which Vaccine Stocks Will Make You a Fortune in 2022?

South Korea has granted approval to the COVID-1i9 vaccine developed by Novavax Inc. NVAX, -3.19% in adults aged 18 and older, the company said Wednesday. The vaccine, known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be approved for commercial use in South Korea and will be manufactured in the country by SK bioscience.

Novavax' COVID-19 vaccine wins approval in South Korea

GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a Biologics License Application (BLA) from SK bioscience for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization in individuals 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2.

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

Los Angeles, California--(Newsfile Corp. - January 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Final Deadline Today: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Novavax Stock (NVAX)